PMID- 37861752
OWN - NLM
STAT- MEDLINE
DCOM- 20231122
LR  - 20231122
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
VI  - 79
IP  - 12
DP  - 2023 Dec
TI  - Risk of gastric cancer among long-term proton pump inhibitor users: a 
      population-based cohort study.
PG  - 1699-1708
LID - 10.1007/s00228-023-03580-7 [doi]
AB  - PURPOSE: To elucidate whether long-term proton pump inhibitor (PPI) users have an 
      increased gastric cancer (GC) risk. METHODS: We searched the 2009-2019 Korean 
      National Health Insurance Services Database for patients aged > 40 years who 
      claimed for Helicobacter pylori eradication (HPE) during 2009-2014. The GC 
      incidence following a PPI exposure of > 180 cumulative defined daily dose (cDDD) 
      and that following an exposure of < 180 cDDD were compared. The outcome was GC 
      development at least 1 year following HPE. A propensity score (PS)-matched 
      dataset was used for analysis within the same quartiles of the follow-up 
      duration. Additionally, dose-response associations were assessed, and the 
      mortality rates were compared between long-term PPI users and non-users. RESULTS: 
      After PS matching, 144,091 pairs of PPI users and non-users were analyzed. During 
      a median follow-up of 8.3 (interquartile range, 6.8-9.6) years, 1053 and 948 GC 
      cases in PPI users and non-users, respectively, were identified, with the GC 
      incidence (95% confidence interval (CI)) being 0.90 (0.85-0.96) and 0.81 
      (0.76-0.86) per 1000 person-years, respectively. The adjusted hazard ratio (aHR) 
      for GC with PPI use was 1.15 (95% CI, 1.06-1.25). Among PPI users, patients in 
      the highest tertile for annual PPI dose showed higher GC development than those 
      in the lowest tertile (aHR (95% CI): 3.87 (3.25-4.60)). GC-related mortality did 
      not differ significantly between PPI users and non-users. CONCLUSION: In this 
      nationwide analysis in Korea, where the GC prevalence is high, long-term PPI use 
      after HPE showed a significant increase in GC, with a positive dose-response 
      relationship.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Kim, Jong Wook
AU  - Kim JW
AD  - Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, 
      Korea.
FAU - Jung, Hye-Kyung
AU  - Jung HK
AD  - Department of Internal Medicine, College of Medicine, Ewha Womans University, 
      Seoul, Korea. junghk@ewha.ac.kr.
FAU - Lee, Bora
AU  - Lee B
AD  - Institute of Health & Environment, Seoul National University, Seoul, Korea.
FAU - Shin, Cheol Min
AU  - Shin CM
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seongnam, Korea.
FAU - Gong, Eun Jeong
AU  - Gong EJ
AD  - Department of Internal Medicine, Hallym University College of Medicine, 
      Chuncheon, Korea.
FAU - Hong, Jitaek
AU  - Hong J
AD  - Department of Internal Medicine, College of Medicine, Ewha Womans University, 
      Seoul, Korea.
FAU - Youn, Young Hoon
AU  - Youn YH
AD  - Department of Internal Medicine, Yonsei University Gangnam Severance Hospital, 
      Seoul, Korea.
FAU - Lee, Kwang Jae
AU  - Lee KJ
AD  - Department of Gastroenterology, Ajou University School of Medicine & Graduate 
      School of Medicine, Suwon, Korea.
LA  - eng
GR  - HC19C0060/National Evidence-based Healthcare Collaborating Agency/
PT  - Journal Article
DEP - 20231020
PL  - Germany
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - *Stomach Neoplasms/chemically induced/epidemiology
MH  - Proton Pump Inhibitors/adverse effects
MH  - Cohort Studies
MH  - Risk
MH  - Proportional Hazards Models
MH  - Risk Factors
OTO - NOTNLM
OT  - Eradication
OT  - Gastric neoplasms
OT  - Helicobacter pylori
OT  - Proton pump inhibitors
EDAT- 2023/10/20 12:44
MHDA- 2023/11/22 06:43
CRDT- 2023/10/20 11:06
PHST- 2023/07/24 00:00 [received]
PHST- 2023/10/07 00:00 [accepted]
PHST- 2023/11/22 06:43 [medline]
PHST- 2023/10/20 12:44 [pubmed]
PHST- 2023/10/20 11:06 [entrez]
AID - 10.1007/s00228-023-03580-7 [pii]
AID - 10.1007/s00228-023-03580-7 [doi]
PST - ppublish
SO  - Eur J Clin Pharmacol. 2023 Dec;79(12):1699-1708. doi: 10.1007/s00228-023-03580-7. 
      Epub 2023 Oct 20.